TOKYO, July 20, 2021 / PRNewswire / – OriCiro Genomics, a pioneer in cell-free synthesis and large-scale genome-wide DNA amplification for advanced therapies and synthetic biology, today announced it has raised 800 million yen in Series B funding led by The University of Tokyo Edge Capital Partners (UTEC) with the participation of ITOCHU Technology Ventures (ITV). OriCiro also received a long-term loan of 200 million yen from the Japan Finance Corporation (JFC), a government-affiliated financial institution, totaling 1 billion yen in this round of financing. The accumulated fund raised since its creation amounts to 1.4 billion euros.
OriCiro has been advancing his business since its inception by december 2018 based on the company’s world’s first cell-free cloning technology for large circular DNA for which conventional PCR methods are not applicable. Major milestones include the launch of our first product, the OriCiro Cellless Cloning System, which enables cell-free amplification of large circular DNA, eliminating reliance on E. coli cloning. In addition to the current research reagents business, OriCiro aims for rapid growth by launching new businesses, including the supply of plasmid DNA for pharmaceutical use and drug discovery services. The proceeds of this financing will be used for strategic purposes, including:
- Develop manufacturing capacities
- Advance R&D
- Creation of an American subsidiary aimed at the growth of the company in the United States
- Speed up the filing of patents
- Recruit the talents required for the above activities
“Cell-free processes are an enabling factor for the development and advancement of gene and cell therapies and synthetic biology,” said Seiji Hirasaki, CEO of OriCiro Genomics. In addition to lead investor UTEC, OriCiro welcomed ITV as a new investor in this round. “The continued assistance of UTEC and the participation of ITV which is supported by one of the largest trading companies in Japan, ITOCHU Corporation, will enable OriCiro to develop and deliver revolutionary products and services using its innovative cellless technology, ”adds Hirasaki.
“OriCiro has a promising technology platform that is expected to support the growth of the global synthetic biology industry. We look forward to the advancement of upcoming projects as a drug discovery platform,” said Atsushi Usami, Ph.D., partner and director of the board of UTEC.
“OriCiro fits well with ITV’s investment philosophy of investing in small businesses that have high potential to change the world. We will fully help OriCiro achieve its business goals, including making technology company cell-free a new global standard for DNA cloning and manufacturing ”commented Koji Abe, Senior Vice President and Partner of ITV.
About OriCiro Genomics
OriCiro is focused on the development and commercialization of large-scale genome-scale cell-free DNA synthesis and amplification technology for applications in gene and cell therapy and synthetic biology. OriCiro’s proprietary technology is positioned to unleash the possibility of advanced therapy and synthetic biology by providing a powerful tool used for research, development and manufacturing across multiple industries including pharmaceutical, diagnostic, agricultural and food. The company is located at Tokyo, Japan. For more information, please visit https://www.ec.oriciro.com/
Contact : Shigemasa Sasaki
Phone: + 81-7044302005
E-mail: [email protected]
SOURCE OriCiro Genomics, Inc.